Effectiveness of Tamsulosin compared with Mirabegron in treatment of Double-J Stent-Related Lower Urinary Tract Symptoms

Alexander, King; Palinrungi, Achmad M.; Palinrungi, Muhammad Asykar; Kholis, Khoirul; Syahrir, Syakri; Faruk, Muhammad

doi:10.5455/ijmrcr.double-j-stent-related-lower-urinary-tract-symptoms

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In disagreement with our study, Alexander et al [22] reported that in groups with tamsulosin 5 mg/day treatment compared with mirabegron 50 mg/day gives a good effect in lowering the complaint score lower urinary tract symptoms for four weeks post-installation of double-J (DJ) stent, urinary symptoms concluding that tamsulosin therapy compared with mirabegron can effectively cure complaints of post-installation lower urinary tract symptoms. The difference can be attributed to smaller sample size in Alexander [22] study (25 patients in each group in Alexander study [22] vs 50 patients in our study).…”

Section: Discussioncontrasting

confidence: 99%

“…In discordance with our study, Alexander et al [22] reported that in groups with tamsulosin 5 mg/day treatment compared with mirabegron 50 mg/day gives a significantly better effect in lowering the pain. The difference can be attributed to the smaller sample size in Alexander study [22].…”

Section: Discussioncontrasting

confidence: 99%

“…In disagreement with our study, Alexander et al [22] reported superiority of tamsulosin over mirabegron in reduction of additional problems. The difference can be attributed to the smaller sample size in Alexander study [22].…”

Section: Discussioncontrasting

confidence: 99%

See 2 more Smart Citations

Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin

Elmarakbi,

Elsayed,

Mohamed

et al. 2024

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

Background Inserting ureteral stents is a routine intervention that often results in problems. The cornerstone for treating stent-related symptoms is pharmacological therapy. This study was conducted to evaluate and to compare the effectiveness of mirabegron, tamsulosin, solifenacin and control in reducing double-J stent-related symptoms. Results Patients were evaluated preoperatively, one week after stent insertion and two weeks after the start of medications by the Ureteral Stent Symptom Questionnaire (USSQ), International Prostate Symptom Score (IPSS), overactive bladder questionnaire (OAB-q) and visual analogue pain scale (VAPS). Solifenacin and mirabegron groups had significantly lower sexual scores after the 1st and 2nd weeks post-operatively (PO) when compared with the control group. Mirabegron group had significantly lower sexual scores after 1st and 2nd weeks PO when compared with patients in tamsulosin and solifenacin groups. Patients in mirabegron group had significantly fewer additional problems after the 1st and 2nd weeks PO when compared with patients in the control and tamsulosin groups. Conclusions To sum up, mirabegron was found to be superior to solifenacin in lowering urinary symptoms scores, sexual performance scores and work performance scores at both first and second weeks post-operatively. Mirabegron is a good alternative choice for SRSs when tamsulosin or solifenacin is ineffective or not tolerated.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin

Elmarakbi,

Elsayed,

Mohamed

et al. 2024

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

show abstract

“…In our study, both Mirabegron and Tamsulosin demonstrated efficacy in reducing urinary, pain, additional, working, and general health scores, consistent with findings reported by Alexander et al [7]. Notably, Mirabegron was more effective than Tamsulosin in reducing pain and working health scores, aligning with previous studies [19].…”

Section: Discussionsupporting

confidence: 92%

Comparison of Mirabegron and Tamsulosin in Alleviating Symptoms from Ureteral Stents: Insights from a Single-Center Institutional Study

Merchant,

Ilamkar,

Pathak

et al. 2024

JCR

View full text Add to dashboard Cite

Background: Indwelling ureteric stents commonly induce complications that significantly affect patients' quality of life. Despite the widespread use of pharmacological interventions such as alpha-blockers and anti-muscarinic agents, their efficacy remains debatable. The beta-3 agonist Mirabegron has emerged as a potential alternative, yet comparative studies with Tamsulosin within a single institutional setting are lacking. Methodology: This prospective observational study enrolled 60 patients with unilateral DJ stents following various urological procedures. Patients were divided into Mirabegron and Tamsulosin groups based on consultant preference. Symptom assessment was performed using the USSQ questionnaire at 7 th and 14 th post-operative days. Results: Both Mirabegron and Tamsulosin effectively reduced urinary, pain, additional, working, and general health scores. Mirabegron demonstrated superior efficacy in reducing pain and improving working health scores compared to Tamsulosin. However, no significant difference was observed in urinary, general, sexual, and additional scores between the two drugs. Conclusion: Mirabegron, particularly at a dosage of 25 mg once daily, emerges as a promising option for relieving ureteral stent-related symptoms, especially pain and working health score. However, further research is needed to optimize treatment strategies and elucidate the underlying mechanisms of action.

show abstract

Effectiveness of Tamsulosin compared with Mirabegron in treatment of Double-J Stent-Related Lower Urinary Tract Symptoms

Cited by 2 publications

References 0 publications

Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin

Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin

Comparison of Mirabegron and Tamsulosin in Alleviating Symptoms from Ureteral Stents: Insights from a Single-Center Institutional Study

Contact Info

Product

Resources

About